






























The discovery of anti-aging drugs is no longer a fantasy. 
Numerous genes for aging and longevity have been 
identified in diverse organisms, revealing potential 
targets for potential anti-aging drugs. But how could 
potential anti-aging drug be introduced to humans? There 
are two problems. First, the effect of anti-aging agents on 
human aging may require almost a lifetime to determine 
[1]. Second, it is seemingly desirable to test anti-aging 
drugs in healthy individuals. However, all drugs have 
side effects. And, in healthy individuals, side effects 
would preclude clinical trials. How might these problems 
be solved? How could we validate anti-aging drugs in 




The solution includes two steps. First, we must find an 
indication for a drug to treat at least one chronic 
disease. Then this drug could be tested in humans, not 
as an anti-aging drug, but as therapy for a particular 
disease. In fact this approach has been suggested for 























































Second, we must find a biomarker of aging that 
absolutely predicts longevity. Then using this 
biomarker, the anti-aging effect could be evaluated in 
the same patients. 
 
Aging and age-related diseases 
 
Aging can be defined as an increase in the probability of 
death. This is how the rate of aging can be measured. 
Humans die not from ‘healthy’ aging but from age-
related diseases. Healthy aging (a late onset of disease) 
is associated with longevity. For example, centenarians 
show significant delay in the onset of age-related 
diseases, including cardiovascular disease, type 2 
diabetes, cancer and Alzheimer’s disease. In other 
words, those who live longer are healthier and vice 
versa [4, 5]. Since, by definition, all age-dependent 
diseases are connected with aging, these diseases are 
connected to each other. In fact, aging humans often 
suffer from many diseases simultaneously: diabetes, 
atherosclerosis, hypertension, macular degeneration, 
prostate enlargement and prostate cancer (in men) or 
breast cancer (in women), Alzheimer’s disease and 
osteoarthritis. This is why elimination of one disease 
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lifespan. And as calculated, “the complete resolution of 
Alzheimer’s disease would add about 19 days onto 
average life expectancy” [6]. But if a drug delays or 
stops all diseases, a person must live longer. Otherwise 
what would be the cause of death, if all causes were 
delayed? Since human longevity is limited by death 
from age-related diseases, a true anti-aging drug must 
delay age-related diseases. In other words, unless a drug 
delays age-related diseases, it will not extend lifespan. 
And vice versa, if a drug prevents age-related diseases, 
it must extend life span. 
 
Biomarker of organismal aging 
 
Given that (a) an increase in the death rate is a measure 
of aging and (b) the death rate is determined diseases 
taken together, then we can conclude that the sum of all 
age-related diseases is the best biomarker of aging. Any 
one age-related disease is not a biomarker of aging 
because, in addition to aging, numerous factors 
contribute to the incidence of a particular disease. For 
example, smoking increases the risk for lung cancer but 
not for Parkinson’s disease. Yet, aging is a risk factor 
for both diseases. And, even for lung cancer, aging is a 
bigger risk factor than is smoking. Aging is the biggest 
risk factor for all age-related diseases. Whether aging 
and disease have a common mechanism or whether 
aging simply increases vulnerability to diseases, in any 
case, the inhibition of aging will delay diseases, thus 
extending life span. 
 
Disease-specific drugs versus anti-aging agents 
 
Slowing aging would delay all age-related diseases. If a 
drug is effective against one particular disease only, 
such a drug is not anti-aging. And current drugs are not 
anti-aging. For example, insulin compensates diabetes. 
Yet, insulin does not treat cancer. And vice versa 
chemotherapy may treat cancer but does not treat 
diabetes. So neither chemotherapy nor insulin is an anti-
aging modality. Furthermore, both insulin and 




The underlying cause of age-related type II diabetes is 
insulin resistance. Insulin treatment does not ‘treat’ the 
cause, it just compensates for resistance. Unlike insulin, 
metformin, an oral anti-diabetic drug, restores insulin 
sensitivity in type diabetes type II. Remarkably, 
metformin decreases the incidence of breast cancer [7, 
8]. Also, metformin is considered for cancer treatment 
[9] and inhibits atherosclerosis in diabetic mice [10]. 
Metformin is used to induce ovulation in patients with 
polycystic ovary syndrome (PCOS). Six months of 1700 
mg/d metformin treatment improved fertility in 
anovulatory PCOS women [11, 12]. Given such effects 
on infertility, type II diabetes, cancer and 
atherosclerosis, it is plausible that metformin slows 
aging. In fact, it extends life span in rodents [13-15]. 
 
Calorie restriction  
 
Calorie restriction (CR) extends life span from yeast 
and worms to rodents and perhaps humans [16-18]. If 
we did not already know that CR slows aging, how 
might we figure that out based solely on clinical data? 
Unrestricted food consumption leads to obesity 
associated with diabetes, atherosclerosis, thrombosis, 
hypertension, cancer (especially breast, prostate and 
colon cancer), coronary heart disease, stroke, 
osteoporosis and Alzheimer’s disease [19-25].  In other 
words, unrestricted eating in humans (ad libitum in 
rodents) accelerates most, if not all, diseases of aging. 
So we can conclude that CR delays all diseases of 
aging. This suggests that CR is an anti-aging modality. 
And it is known that CR extends life span in almost all 
organisms from yeast to mammals.  
 
From metformin and calorie restriction to rapamycin 
 
Numerous factors including insulin, glucose and amino 
acids activate the nutrient-sensing TOR (target of 
rapamycin) pathway. When the TOR pathway is 
activated, it acts via S6K to deplete the insulin-receptor-
substrate (IRS1/2), causing insulin resistance (Figure 1).  
As shown in Figure 1, metformin indirectly (by 
activating AMPK) inhibits TOR and thereby restores 
insulin sensitivity [26].  
 
CR decreases levels of nutrients and insulin and thus 
de-activates TOR (Figure 1). It is possible that the anti-
aging effects of CR and metformin are due to inhibition 
of the TOR pathway. Like CR, rapamycin decreases 
size of fat cells and animal weight. When rats (15 weeks 
old) were either treated 1 mg/kg rapamycin 3 times per 
week for 12 weeks, rapamycin decreased their weight. 
Mean adipocyte diameter was decreased from 36 µm to 
25 µm. At the end of the study, mean body weight in the 
rapamycin-treated rats was 356 g instead of 507 g, in 
spite of comparable food intake [27]. So rapamycin 
imitated CR. CR may also extend life span by activating 
sirtuins. Probably, sirtuins, AMPK and mTOR are 
linked in the common network [28]. 
 
Genetic inhibition of the TOR pathway slows down 
aging in diverse organisms, including yeast, worms, 
flies and mice [29-33]. If genetic inhibition of the 
TOR pathway slows aging, then rapamycin, a drug that  
   




























inhibits TOR, must slow aging too. Once used for any 
indication, even unrelated to age-related diseases (such 
as renal transplantation, for instance), an anti-aging 
drug should slow down age-related diseases such as 
cancer, osteoporosis and atherosclerosis. Rapamycin is 
already used in renal transplant patients. 
 
Retrospective analysis of the clinical use of rapamycin 
 
Rapamycin has been used in renal-transplant patients 
for several years. Since rapamycin was viewed as an 
immunossupressive drug (not as an anti-aging drug) it 
was expected that it would cause cancer.  
 
Unexpectedly, it turned out that rapamycin prevented 
cancer, and even cured pre-existing cancer and Kaposi’s 
sarcoma in renal transplant patients [34-44]. 
Furthermore, temsirolimus, an analog of rapamycin, has 
recently been approved for cancer therapy [45]. Also, 
everolimus, a TOR inhibitor, markedly delayed tumor 
development in transgenic mice that spontaneously 
develop ovarian carcinomas [46]. Would TOR 
inhibitors extend life span in transgenic mice? Since 
rapamycin delays cancer, it must prolong the life span 
of cancer-prone mice, who would otherwise die from 
cancer. Of course, humans die from a variety of age-
































life span dramatically, rapamycin must delay most of 
them. 
 
In renal transplant patients, rapamycin increases blood 
lipoproteins [47]. This is considered to be a negative 
side effect. Yet, this results from mobilization of fat 
from the fat tissue (lipolysis) [48, 49]. This is exactly 
what happens during starvation or calorie restriction 
(CR). And CR extends life span. Furthermore, 
rapamycin reduces the accumulation of cholesterol 
within the arterial wall [50, 51]. Thus, lipolysis of fat 
tissue and decreased uptake of cholesterol by tissues 
both contribute to high levels of lipids in blood (Figure 
2). Despite hypercholesterolemia, rapamycin prevents 
atherosclerosis in animals [52]. In animal models, 
systemic administration of rapamycin reduces 
neointimal thickening and slows the progression of 
atherosclerosis in apoE-deficient mice with elevated 
levels of cholesterol [53-55]. In patients with coronary 
atherosclerosis, oral rapamycin prevents re-stenosis 
after implantation of metal stents [56]. As a case report, 
it has been described that conversion to everolimus (an 
analog of rapamycin) resulted in decrease in blood 
pressure [57]. In kidney transplant patients, 2 years after 
transplantation, body-mass index was significantly 
lower in the rapamycin-based treatment arm compared 
to cyclosporine [27]. 
   































Multiple indications for a single drug 
 
If a drug is indicated to treat most age-related diseases, 
then this drug could be defined as an anti-aging drug. 
The probability that a non-anti-aging drug would have 
independent activities against all diseases is exceedingly 
low. 
 
Rapamycin analogs are approved to treat certain cancers 
[45]. Based on preclinical data, rapamycin has been 
considered in such pathologies as obesity [58], 
atherosclerosis [53-55], cardiac hypertrophy [59-64], 
aortic aneurysm [65], osteoporosis [66-68], organ 
fibrosis ( liver, renal, cardiac fibrosis) [64, 69, 70-75], 
neurodegeneration [76, 77], Alzheimer's disease [78, 
79], Parkinson’s disease [80-82], psoriasis [80], skin 
scars and keloids [83], multiple sclerosis [84], arthritis 
[85, 86], and renal hypertrophy in diabetes [87]. 
 
May rapamycin increase human life span? 
 
In principle, life-extending effect of anti-aging drug 
might be limited by side effects. Although chronic 
administration of rapamycin is associated with some 
undesirable effects in transplant patients (see for 
references [88]), they might be avoided by 
administrating rapamycin in pulses (for example, once a 
week). For example, chronic administration of 
rapamycin impairs wound healing. In theory, a pulse 
treatment might rejuvenate wound-healing cells [88]. A 
single dose of rapamycin reverses insulin resistance, 
whereas chronic administration of rapamycin may 
precipitate diabetes in certain conditions. Clinical trials 
will be needed to determine benefits of pulse treatment 
with rapamycin. Alternatively, rapamycin can be 
combined with ‘complementary’ drugs. Thus, 
hyperlipidemia caused by rapamycin may deteriorate 
insulin-resistance. Yet, hyperlipidemia caused by 
rapamycin can be controlled by lipid-lowering drugs. A 





Resveratrol, an activator of SIRT1 in mammals, extends 
life span in diverse species. [89, 90] Resveratrol was 
shown to prevent cancer, atherosclerosis, neuro-
degeneration and insulin-resistance (diabetes type II) 
[10, 91-100]. Resveratrol also indirectly inhibits PI-
3K/mTOR/S6K pathway [101-105]. SIRT1 and mTOR 
could be members of the same sirtuin/TOR network. 
The link between TOR and sirtuins has been suggested 
[28]. It is likely that TOR (pro-aging pathway) and 
sirtuins (anti-aging pathway) antagonize each other 
[106]. However, inhibition of the TOR pathway by 
resveratrol occurs at near-toxic concentrations [107]. 
Figure  2.  Re‐interpretation  of  the  hyperlipidemic  side
effect of rapamycin. Rapamycin activates adipose tissue lipase,





The ability of resveratrol to extend life span may be 
limited by its toxicity at high doses due to off-target 
effects. Therefore, more selective activators of SIRT1 
undergo clinical trials [3]. Importantly, these drugs will 
be developed to treat age-related diseases such as type 2 
diabetes [3]. This is the only possible strategy for a drug 
to enter the clinic. But here is an additional aspect: this 
is the only practical way of how anti-aging effect can be 
evaluated too. Once used for treatment of diabetes, 
sirtuin activators might delay heart diseases, cancer, 
neurodegeneration and other age-related diseases in the 
same patients. And delaying of all diseases must extend 





It was previously assumed that anti-aging drugs should 
be tested in healthy individuals. Ironically, the best 
biomarker of aging is the occurrence of age-related 
diseases. And this is how anti-aging drugs can be 
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aging drug can prevent or delay the onset of all age-
related diseases). Then such drugs could be approved 
for prevention of any particular age-related disease in 
healthy individuals. Thus, potential anti-aging drugs 
should be introduced to the clinical trials for therapy of 
a particular disease but be ultimately approved for 
prevention of all age-related diseases in healthy 
individuals. And this is synonymous to the approval of a 
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